
Reena Rao

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7534973/publications.pdf Version: 2024-02-01



REENA RAO

#	Article	IF	CITATIONS
1	Vasopressin Receptor Type-2 Mediated Signaling in Renal Cell Carcinoma Stimulates Stromal Fibroblast Activation. International Journal of Molecular Sciences, 2022, 23, 7601.	4.1	1
2	Integrin β1 Promotes Pancreatic Tumor Growth by Upregulating Kindlin-2 and TGF-β Receptor-2. International Journal of Molecular Sciences, 2021, 22, 10599.	4.1	7
3	The tyrosine-kinase inhibitor Nintedanib ameliorates autosomal-dominant polycystic kidney disease. Cell Death and Disease, 2021, 12, 947.	6.3	20
4	Targeting the vasopressin type-2 receptor for renal cell carcinoma therapy. Oncogene, 2020, 39, 1231-1245.	5.9	31
5	Glycogen Synthase Kinase-3 Signaling in Acute Kidney Injury. Nephron, 2020, 144, 609-612.	1.8	10
6	Glycogen synthase kinaseâ€3β inhibits tubular regeneration in acute kidney injury by a FoxM1â€dependent mechanism. FASEB Journal, 2020, 34, 13597-13608.	0.5	20
7	Epithelial Vasopressin Type-2 Receptors Regulate Myofibroblasts by a YAP-CCN2–Dependent Mechanism in Polycystic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2020, 31, 1697-1710.	6.1	26
8	MCP-1 promotes detrimental cardiac physiology, pulmonary edema, and death in the <i>cpk</i> model of polycystic kidney disease. American Journal of Physiology - Renal Physiology, 2019, 317, F343-F360.	2.7	19
9	A cAMP and CREB-mediated feed-forward mechanism regulates GSK3 β in polycystic kidney disease. Journal of Molecular Cell Biology, 2016, 8, 464-476.	3.3	16
10	Enhancing Nephrology Career Interest through the ASN Kidney TREKS Program. Journal of the American Society of Nephrology: JASN, 2016, 27, 1604-1607.	6.1	19
11	Glycogen synthase kinase-3 inhibition attenuates fibroblast activation and development of fibrosis following renal ischemia/reperfusion in mice. DMM Disease Models and Mechanisms, 2015, 8, 931-40.	2.4	50
12	Glycogen synthase kinase-3β promotes cyst expansion in polycystic kidney disease. Kidney International, 2015, 87, 1164-1175.	5.2	39
13	Glycogen synthase kinase 3α regulates urine concentrating mechanism in mice. American Journal of Physiology - Renal Physiology, 2015, 308, F650-F660.	2.7	26
14	Glycogen Synthase Kinaseâ€3 Inhibition Reduces Renal Cystogenesis in Polycystic Kidney Disease. FASEB Journal, 2013, 27, 1115.20.	0.5	0
15	Specific deletion of glycogen synthase kinase-3β in the renal proximal tubule protects against acute nephrotoxic injury in mice. Kidney International, 2012, 82, 1000-1009.	5.2	47
16	Glycogen synthase kinase-3 regulation of urinary concentrating ability. Current Opinion in Nephrology and Hypertension, 2012, 21, 541-546.	2.0	25
17	GSK3β Mediates Renal Response to Vasopressin by Modulating Adenylate Cyclase Activity. Journal of the American Society of Nephrology: JASN, 2010, 21, 428-437.	6.1	71
18	Glycogen Synthase Kinase 3 Inhibition Improves Insulin Stimulated Glucose Metabolismin High Fat Fed C57/BL6J Mice. FASEB Journal, 2007, 21, A832.	0.5	0

#	Article	IF	CITATIONS
19	Lithium treatment inhibits renal GSK-3 activity and promotes cyclooxygenase 2-dependent polyuria. American Journal of Physiology - Renal Physiology, 2005, 288, F642-F649.	2.7	113
20	Hypertonic Stress Activates Glycogen Synthase Kinase 3β-mediated Apoptosis of Renal Medullary Interstitial Cells, Suppressing an NFή-driven Cyclooxygenase-2-dependent Survival Pathway. Journal of Biological Chemistry, 2004, 279, 3949-3955.	3.4	80